Concepedia

Zhilin Shen

ZS

Statistics

Publications

5

Citations

223

H-Index

5

Active since

2021

Affiliations

Betta Pharmaceuticals (China)(Current)

Jilin University

Sun Yat-sen University Cancer Center

Zhejiang University

Nanjing General Hospital of Nanjing Military Command

Zhilin Shen is an author at Betta Pharmaceuticals (China).

Publications per year

2021–2023

5

Publications

5

TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell

Zhengcheng Wang, Xiang Ao, Zhilin Shen et al. · International Journal of Biological Sciences · 2021 · 87 citations · Full text

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial

Wei Ou, Ning Li, Bao-Xiao Wang et al. · EClinicalMedicine · 2023 · 45 citations · Full text

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing

Yunpeng Yang, Jie Huang, Tao Wang et al. · Journal of Thoracic Oncology · 2021 · 43 citations · Full text

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity

Chris Liang, Xiaobin Yuan, Zhilin Shen et al. · Molecular Therapy — Oncolytics · 2022 · 27 citations · Full text

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Shun Lü, Yiping Zhang, Guojun Zhang et al. · Journal of Thoracic Oncology · 2022 · 21 citations · Full text

1–5 of 5